A respiratory syncytial virus (RSV) Anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice

Journal of Virology

Volumn 87, Issue 20, 2013, Pages 10955-10967

  Boyoglu Barnum, Seyhan ^a   Gaston, Kelsey A ^a   Todd, Sean O ^a   Boyoglu, Cemil ^a   Chirkova, Tatiana ^a   Barnum, Thomas R ^b   Jorquera, Patricia ^a,b   Haynes, Lia M ^c   Tripp, Ralph A ^b   Moore, Martin L ^a   Anderson, Larry J ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY 131 2G; MUCIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BREATHING; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFECTION PREVENTION; INFLAMMATORY INFILTRATE; LUNG INFILTRATE; MOUSE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH2 CELL; VIRUS REPLICATION; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED BALB C; MUCUS; RESPIRATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84886921793     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01164-13     Document Type: Article

References (78)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555.
2. Groothuis JR, Simoes E, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Van Raden M, Hemming VG. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to highrisk infants and young children Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. 329:1524-1530.
3. IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537.
4. Geevarghese B, Simões EA. 2012. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir. Ther. 17:201-211.
5. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am. J. Infect. Control 35(Suppl 2):S65-S164.
6. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162: 80-99.
7. Graham BS. 2011. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 239: 149-166.
8. Connors M, Collins PL, Firestone CY, Murphy BR. 1991. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65:1634-1637.
9. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL. 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. U. S. A. 83:7462-7466.
10. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, Wertz GW. 1987. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:3855-3861.
11. Tripp RA. 2004. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 17:165-181.
12. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73:7099-7107.
13. Tripp RA, Jones L, Anderson LJ. 2000. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J. Virol. 74:6227-6229.
14. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. 2003. Enhanced disease and pulmonary eosinophilia associated with formalininactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance. P. J. Virol. 77:9831-9844.
15. Tripp RA, Moore D, Winter J, Anderson LJ. 2000. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J. Virol. 74:1614-1622.
16. Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. 2003. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance. P. J. Virol. 77:6580-6584.
17. + T cell responses. J. Immunol. 176:1600-1608.
18. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:732-738.
19. Anderson LJ, Hierholzer JC, Stone YO, Tsou C, Fernie BF. 1986. Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J. Clin. Microbiol. 23:475-480.
20. Anderson LJ, Bingham P, Hierholzer JC. 1988. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J. Virol. 62:4232-4238.
21. Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, Anderson LJ. 2009. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J. Infect. Dis. 200:439-447.
22. 2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 90:1119-1123.
23. Radu GU, Caidi H, Miao C, Tripp RA, Anderson LJ, Haynes LM. 2010. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)- challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J. Virol. 84:9632-9636.
24. Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, Olson SJ, Ho SB, Peebles RS, Jr. 2006. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am. J. Pathol. 169:977-986.
25. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE, Jr, Goleniewska K, Williams JV, Collins PL, Peebles RS, Jr. 2009. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J. Virol. 83:4185-4194.
26. Hershey GK. 2003. IL-13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol. 111:677-690.
27. Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, DeKruyffRH, Umetsu DT. 2001. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167:4668-4675.
28. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788.
29. de Waal L, Koopman LP, van Benten IJ, Brandenburg AH, Mulder PG, de Swart RL, Fokkens WJ, Neijens HJ, Osterhaus AD. 2003. Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection. J. Med. Virol. 70:309-318.
30. Lugo RA, Nahata MC. 1993. Pathogenesis and treatment of bronchiolitis. Clin. Pharm. 12:95-116.
31. Quinn SF, Erickson S, Oshman D, Hayden F. 1985. Lobar collapse with respiratory syncytial virus pneumonitis. Pediatr. Radiol. 15:229-230.
32. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360:588-598.
33. Moore ML, Peebles RS, Jr. 2006. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacol. Ther. 112:405-424.
34. Anderson LJ, Hierholzer JC, Bingham PG, Stone YO. 1985. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 22:1050-1052.
35. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Amer. J. Hyg. 27:493-497.
36. Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, Schrag SJ, Taylor TH, Jr, Beall BW, Breiman RF, Feikin DR, Njenga MK, Mayer LW, Oberste MS, Tondella ML, Winchell JM, Lindstrom SL, Erdman DD, Fields BS. 2011. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J. Clin. Microbiol. 49:2175-2182.
37. Tripp RA, Barskey A, Goss L, Anderson LJ. 2002. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J. Neuroimmunol. 129:141-153.
38. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, Hotard A, Sherrill TP, Peebles RS, Jr, Moore ML. 2011. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J. Virol. 85: 5782-5793.
39. Empey KM, Peebles RS, Kolls JK. 2010. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50:1258-1267.
40. Ottolini MG, Curtis SJ, Porter DD, Mathews A, Richardson JY, Hemming VG, Prince GA. 2002. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. 46:2299-2302.
41. Andersson C, Liljestrom P, Stahl S, Power UF. 2000. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen. FEMS Immunol. Med. Microbiol. 29:247-253.
42. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM. 2009. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J. Immunol. 183:6338-6345.
43. Hashimoto K, Graham BS, Ho SB, Adler KB, Collins RD, Olson SJ, Zhou W, Suzutani T, Jones PW, Goleniewska K, O'Neal JF, Peebles RS, Jr. 2004. Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. Am. J. Respir. Crit. Care Med. 170:306-312.
44. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. 2010. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2:655-661.
45. Bembridge GP, Garcia-Beato R, Lopez JA, Melero JA, Taylor G. 1998. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J. Immunol. 161: 2473-2480.
46. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791.
47. Johnson TR, Graham BS. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73:8485-8495.
48. Shingai M, Azuma M, Ebihara T, Sasai M, Funami K, Ayata M, Ogura H, Tsutsumi H, Matsumoto M, Seya T. 2008. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFNbeta induction. Int. Immunol. 20:1169-1180.
49. Sparer TE, Matthews S, Hussell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJ. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine- enhanced lung eosinophilia. J. Exp. Med. 187:1921-1926.
50. Tebbey PW, Hagen M, Hancock GE. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1967-1972.
51. Arnold R, Konig B, Werchau H, Konig W. 2004. Respiratory syncytial virus deficient in solubleGprotein induced an increased proinflammatory response in human lung epithelial cells. Virology 330:384-397.
52. Ray R, Hoft DF, Meyer K, Brown R, Lagging LM, Belshe RB. 2001. Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus. Virus Res. 75:147-154.
53. Johnson TR, McLellan JS, Graham BS. 2012. Respiratory syncytial virus glycoproteinGinteracts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J. Virol. 86:1339-1347.
54. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karron RA, Collins PL, Kleeberger SR. 2005. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl. Acad. Sci. U. S. A. 102:8996-9001.
55. Bukreyev A, Serra ME, Laham FR, Melendi GA, Kleeberger SR, Collins PL, Polack FP. 2006. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J. Virol. 80:5854-5861.
56. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA. 2009. Respiratory syncytial virus proteins modulate suppressors of cytokine sig- naling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol. 22:147-161.
57. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL. 2008. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82:12191-12204.
58. Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344:1917-1928.
59. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J. 1970. Pathological changes in virus infections of the lower respiratory tract in children. J. Clin. Pathol. 23:7-18.
60. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol. 20:108-119.
61. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, Velozo L, Jafri H, Chavez-Bueno S, Ogra PL, McKinney L, Reed JL, Welliver RC, Sr. 2007. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 195:1126-1136.
62. Rose MC, Voynow JA. 2006. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol. Rev. 86:245-278.
63. Cockcroft DW, Davis BE. 2006. Mechanisms of airway hyperresponsiveness. J. Allergy Clin. Immunol. 118:551-559.
64. Holgate ST, Polosa R. 2008. Treatment strategies for allergy and asthma. Nat. Rev. Immunol. 8:218-230.
65. Perkins C, Yanase N, Smulian G, Gildea L, Orekov T, Potter C, Brombacher F, Aronow B, Wills-Karp M, Finkelman FD. 2011. Selective stimulation of IL-4 receptor on smooth muscle induces airway hyperresponsiveness in mice. J. Exp. Med. 208:853-867.
66. Rosenberg HF, Phipps S, Foster PS. 2007. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 119:1303-1310.
67. Vock C, Hauber HP, Wegmann M. 2010. The other T helper cells in asthma pathogenesis. J. Allergy 2010:519298. doi:10.1155/2010/519298.
68. Franova S, Joskova M, Sadlonova V, Pavelcikova D, Mesarosova L, Novakova E, Sutovska M. 2013. Experimental model of allergic asthma. Adv. Exp. Med. Biol. 756:49-55.
69. Deshmane SL, Kremlev S, Amini S, Sawaya BE. 2009. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29:313-326.
70. Foster WM, Adler KB, Crews AL, Potts EN, Fischer BM, Voynow JA. 2010. MARCKS-related peptide modulates in vivo the secretion of airway Muc5ac. Am. J. Physiol. Lung Cell. Mol. Physiol. 299:L345-L352.
71. Tekkanat KK, Maassab H, Berlin AA, Lincoln PM, EvanoffHL, Kaplan MH, Lukacs NW. 2001. Role of interleukin-12 and stat-4 in the regulation of airway inflammation and hyperreactivity in respiratory syncytial virus infection. Am. J. Pathol. 159:631-638.
72. Bortolatto J, Borducchi E, Rodriguez D, Keller AC, Faquim-Mauro E, Bortoluci KR, Mucida D, Gomes E, Christ A, Schnyder-Candrian S, Schnyder B, Ryffel B, Russo M. 2008. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin- 12/gamma interferon axis. Clin. Exp. Allergy 38:1668-1679.
73. Romani L, Puccetti P, Bistoni F. 1997. Interleukin-12 in infectious diseases. Clin. Microbiol. Rev. 10:611-636.
74. Rudd BD, Schaller MA, Smit JJ, Kunkel SL, Neupane R, Kelley L, Berlin AA, Lukacs NW. 2007. MyD88-mediated instructive signals in dendritic cells regulate pulmonary immune responses during respiratory virus infection. J. Immunol. 178:5820-5827.
75. Douglas SD, Leeman SE. 2011. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann. N. Y. Acad. Sci. 1217:83-95.
76. Mionnet C, Buatois V, Kanda A, Milcent V, Fleury S, Lair D, Langelot M, Lacoeuille Y, Hessel E, Coffman R, Magnan A, Dombrowicz D, Glaichenhaus N, Julia V. 2010. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat. Med. 16:1305-1312.
77. Mekseepralard C, Toms GL, Routledge EG. 2006. Protection of mice against human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein. J. Gen. Virol. 87:1267-1273.
78. Low KW, Tan T, Ng K, Tan BH, Sugrue RJ. 2008. The RSV F and G glycoproteins interact to form a complex on the surface of infected cells. Biochem. Biophys. Res. Commun. 366:308-313.